Concepts (136)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hyperoxaluria, Primary | 3 | 2024 | 12 | 1.230 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 2022 | 32 | 0.760 |
Why?
|
| Immunosuppressive Agents | 2 | 2018 | 666 | 0.760 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2022 | 50 | 0.730 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 2018 | 14 | 0.560 |
Why?
|
| Kidney Transplantation | 3 | 2024 | 572 | 0.550 |
Why?
|
| Renal Insufficiency | 3 | 2023 | 250 | 0.540 |
Why?
|
| Nephrotic Syndrome | 1 | 2018 | 52 | 0.540 |
Why?
|
| Kidney Calculi | 3 | 2023 | 46 | 0.530 |
Why?
|
| Rituximab | 1 | 2018 | 174 | 0.510 |
Why?
|
| Acute Kidney Injury | 1 | 2022 | 684 | 0.450 |
Why?
|
| Cytomegalovirus Infections | 2 | 2025 | 224 | 0.370 |
Why?
|
| Organ Transplantation | 2 | 2025 | 172 | 0.370 |
Why?
|
| Antiviral Agents | 2 | 2025 | 812 | 0.290 |
Why?
|
| Urinary Tract Infections | 2 | 2003 | 327 | 0.280 |
Why?
|
| Ganciclovir | 2 | 2025 | 102 | 0.270 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2025 | 1251 | 0.250 |
Why?
|
| Viremia | 1 | 2025 | 132 | 0.210 |
Why?
|
| Early Diagnosis | 1 | 2024 | 191 | 0.200 |
Why?
|
| Nephrocalcinosis | 1 | 2023 | 9 | 0.200 |
Why?
|
| Anti-Infective Agents, Urinary | 1 | 2003 | 8 | 0.200 |
Why?
|
| Nephrolithiasis | 1 | 2023 | 14 | 0.200 |
Why?
|
| RNAi Therapeutics | 1 | 2021 | 17 | 0.180 |
Why?
|
| Coatomer Protein | 1 | 2022 | 29 | 0.180 |
Why?
|
| Hematuria | 1 | 2022 | 48 | 0.180 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2022 | 837 | 0.180 |
Why?
|
| Kidney | 2 | 2018 | 1303 | 0.170 |
Why?
|
| Anti-Bacterial Agents | 2 | 2003 | 2565 | 0.170 |
Why?
|
| Dyspnea | 1 | 2022 | 159 | 0.170 |
Why?
|
| Adolescent | 10 | 2022 | 20899 | 0.160 |
Why?
|
| Adenine | 1 | 2020 | 125 | 0.150 |
Why?
|
| Receptors, Phospholipase A2 | 1 | 2018 | 4 | 0.140 |
Why?
|
| Humans | 18 | 2025 | 131379 | 0.140 |
Why?
|
| Lung Diseases | 1 | 2022 | 400 | 0.140 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 1 | 2017 | 22 | 0.130 |
Why?
|
| Hemodiafiltration | 1 | 2017 | 17 | 0.130 |
Why?
|
| Kidney Diseases | 1 | 2022 | 482 | 0.130 |
Why?
|
| Algorithms | 1 | 2024 | 1683 | 0.130 |
Why?
|
| Ureteral Obstruction | 1 | 2018 | 102 | 0.130 |
Why?
|
| Ureter | 1 | 2018 | 95 | 0.130 |
Why?
|
| Renal Dialysis | 1 | 2024 | 949 | 0.130 |
Why?
|
| Caregivers | 1 | 2022 | 582 | 0.120 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2016 | 81 | 0.120 |
Why?
|
| Child | 10 | 2023 | 26220 | 0.120 |
Why?
|
| Venous Thrombosis | 1 | 2017 | 168 | 0.120 |
Why?
|
| Catheterization, Peripheral | 1 | 2017 | 129 | 0.120 |
Why?
|
| Mycophenolic Acid | 1 | 2015 | 60 | 0.120 |
Why?
|
| Tacrolimus | 1 | 2015 | 104 | 0.110 |
Why?
|
| Cyclosporine | 1 | 2015 | 129 | 0.110 |
Why?
|
| Prednisone | 1 | 2015 | 244 | 0.110 |
Why?
|
| Liver Transplantation | 1 | 2024 | 1129 | 0.110 |
Why?
|
| Parents | 2 | 2022 | 1108 | 0.110 |
Why?
|
| Urogenital Abnormalities | 1 | 2016 | 161 | 0.110 |
Why?
|
| Bias | 2 | 2025 | 144 | 0.100 |
Why?
|
| Communication | 1 | 2018 | 530 | 0.100 |
Why?
|
| Graft Survival | 1 | 2015 | 465 | 0.100 |
Why?
|
| Decision Making | 1 | 2018 | 681 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 1076 | 0.100 |
Why?
|
| Transplant Recipients | 2 | 2025 | 234 | 0.090 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 810 | 0.090 |
Why?
|
| Treatment Outcome | 5 | 2018 | 12915 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 1404 | 0.090 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 1166 | 0.090 |
Why?
|
| Biopsy | 1 | 2015 | 1247 | 0.090 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 1404 | 0.090 |
Why?
|
| Young Adult | 4 | 2023 | 10080 | 0.090 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 1023 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2015 | 572 | 0.080 |
Why?
|
| Infant | 6 | 2022 | 13291 | 0.080 |
Why?
|
| Female | 9 | 2022 | 71018 | 0.080 |
Why?
|
| RNA, Small Interfering | 2 | 2022 | 665 | 0.080 |
Why?
|
| Child, Preschool | 6 | 2022 | 15036 | 0.080 |
Why?
|
| Focus Groups | 2 | 2022 | 227 | 0.080 |
Why?
|
| Kidney Failure, Chronic | 1 | 2017 | 940 | 0.080 |
Why?
|
| Endovascular Procedures | 1 | 2017 | 764 | 0.070 |
Why?
|
| Male | 7 | 2020 | 65099 | 0.070 |
Why?
|
| Quality of Life | 1 | 2018 | 2103 | 0.070 |
Why?
|
| Adult | 5 | 2023 | 31618 | 0.070 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 5267 | 0.060 |
Why?
|
| Time Factors | 1 | 2015 | 6271 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 3411 | 0.060 |
Why?
|
| Acyclovir | 1 | 2024 | 47 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2020 | 17621 | 0.050 |
Why?
|
| Bicarbonates | 1 | 2023 | 98 | 0.050 |
Why?
|
| Oxalates | 1 | 2022 | 22 | 0.050 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2023 | 80 | 0.050 |
Why?
|
| Cause of Death | 1 | 2024 | 510 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2002 | 741 | 0.040 |
Why?
|
| Adenine Phosphoribosyltransferase | 1 | 2020 | 5 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2003 | 705 | 0.040 |
Why?
|
| Urolithiasis | 1 | 2020 | 9 | 0.040 |
Why?
|
| RNA Interference | 1 | 2021 | 496 | 0.040 |
Why?
|
| Acute Disease | 1 | 2003 | 1152 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 3087 | 0.040 |
Why?
|
| Syndrome | 1 | 2022 | 1165 | 0.040 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2020 | 125 | 0.040 |
Why?
|
| Australia | 1 | 2018 | 176 | 0.030 |
Why?
|
| Transplants | 1 | 2018 | 38 | 0.030 |
Why?
|
| Urologic Surgical Procedures | 1 | 2018 | 61 | 0.030 |
Why?
|
| Iohexol | 1 | 2017 | 18 | 0.030 |
Why?
|
| Internationality | 1 | 2018 | 130 | 0.030 |
Why?
|
| Canada | 1 | 2018 | 327 | 0.030 |
Why?
|
| Triiodobenzoic Acids | 1 | 2017 | 30 | 0.030 |
Why?
|
| Constriction, Pathologic | 1 | 2018 | 226 | 0.030 |
Why?
|
| PAX2 Transcription Factor | 1 | 2016 | 27 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2016 | 28 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2016 | 76 | 0.030 |
Why?
|
| Parent-Child Relations | 1 | 2018 | 255 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2017 | 251 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2022 | 1907 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2018 | 289 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2023 | 1098 | 0.030 |
Why?
|
| Anxiety | 1 | 2022 | 1000 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2018 | 700 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 562 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2016 | 371 | 0.030 |
Why?
|
| Contrast Media | 1 | 2017 | 489 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 3832 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2016 | 588 | 0.030 |
Why?
|
| Robotic Surgical Procedures | 1 | 2018 | 235 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2982 | 0.020 |
Why?
|
| Pedigree | 1 | 2016 | 1710 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2016 | 777 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2024 | 3112 | 0.020 |
Why?
|
| Age Factors | 1 | 2017 | 2869 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 1227 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2003 | 8584 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2018 | 5118 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2018 | 3690 | 0.020 |
Why?
|
| Texas | 1 | 2017 | 3614 | 0.020 |
Why?
|
| Prognosis | 1 | 2018 | 4941 | 0.020 |
Why?
|
| Pediatrics | 1 | 2018 | 1230 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 2856 | 0.020 |
Why?
|
| Risk Factors | 1 | 2017 | 10943 | 0.010 |
Why?
|
| United States | 1 | 2018 | 11778 | 0.010 |
Why?
|
| Middle Aged | 1 | 2020 | 28798 | 0.010 |
Why?
|